BioHarvest Sciences to Participate in 38th Annual Roth Conference on March 22-24, 2026
BioHarvest Sciences (NASDAQ: BHST) will participate in the 38th Annual Roth Conference on March 22-24, 2026 at The Ritz-Carlton Laguna Niguel in Dana Point, CA.
Rhea-AI Summary
BioHarvest Sciences (NASDAQ: BHST) will participate in the 38th Annual Roth Conference on March 22-24, 2026 at The Ritz-Carlton Laguna Niguel in Dana Point, CA. CEO Ilan Sobel is scheduled for one-on-one meetings with institutional investors.
According to the company, BioHarvest completed a successful Q4 2025 financing, is fully funded for near-term CapEx, and has over 85,000 direct customers as it focuses on growth in CDMO and consumer product businesses.
Positive
- None.
Negative
- None.
Details
News Market Reaction – BHST
In the Mar 3 session, BHST declined 2.44%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
- Conference dates
- March 22–24, 2026
- 38th Annual Roth Conference schedule
- Conference edition
- 38th Annual
- Roth Conference for growth companies
- Direct customers
- Over 85,000
- BioHarvest Product-side customer base cited by CEO
- Share price
- $4.51
- Pre-news current price from market context
- Daily move
- -4.25%
- 24h price change prior to article publication
- 52-week range
- $4.27–$12.80
- Low and high from market context
- Market cap
- $106,760,826
- Equity value before this news
- 200-day MA
- $7.25
- Long-term trend level; price trading below
Historical Context
-
Shared revenue run rate, margins, and profitability focus in shareholder letter.
-
Award of $1.6M Israeli Innovation Authority grant for platform development.
-
Launch of VINIA Blood Flow Hydration into large U.S. electrolyte market.
-
Reported revenue growth, ongoing net loss, and Q4 guidance with EBITDA range.
-
Conference attendance and highlight of upsized $19.9M equity offering.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
cdmo technical
capex financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - March 3, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced that management has been invited to attend the 38th Annual Roth Conference taking place on March 22-24, 2026.
CEO Ilan Sobel is scheduled to host one-on-one meetings with institutional investors throughout the duration of the event.
38th Annual Roth Conference for Growth Companies
Date: March 22-24, 2026
Location: The Ritz-Carlton Laguna Niguel- Dana Point, CA
Format: 1x1 Meetings
Sobel said: "I am pleased to announce our invitation to the 38th Annual Roth Conference, which is a high-profile opportunity to highlight the BioHarvest story for a select group of sophisticated investors. Our successful Q4 2025 financing round has us at an important inflection point, as we are now fully funded from a near-term CapEx perspective, and focused on driving accelerated growth in both our CDMO and Consumer Product businesses. With now over 85,000 direct customers on our Product side, and anchor CDMO research partnerships, we are well positioned to achieve significant growth milestones in 2026, leveraging novel plant-based compounds in our mission to improve human health and wellness."
Registration is mandatory for conference participation. For more information or to schedule a meeting with management, please contact info@bioharvest.com.
About BioHarvest Sciences Inc.
BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) is a leader in Botanical Synthesis, leveraging its patented technology platform to grow plant-based compounds, without the need to grow the underlying plant. BioHarvest is leveraging its botanical synthesis technology to develop the next generation of science-based and clinically proven therapeutic solutions within two major business verticals; as a contract development and manufacturing organization (CDMO) on behalf of customers seeking novel plant-based compounds, and as a creator of proprietary nutraceutical health and wellness products, which includes dietary supplements. To learn more, please visit www.bioharvest.com.
Forward-Looking Statements
Information set forth in this news release might include forward-looking statements that are based on management's current estimates, beliefs, intentions, and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. There is no assurance of additional future contracts. Readers are cautioned that future contracts or increased revenue is not necessarily an increase in net income or profitability as costs will likely increase as well. All forward-looking statements are inherently uncertain and actual results may be affected by a number of material factors beyond our control. Readers should not place undue reliance on forward-looking statements. BHST does not intend to update forward-looking statement disclosures other than through our regular management discussion and analysis disclosures.
This release has been reviewed and approved by Dave Ryan, VP Investor Relations, who accepts responsibilities for its contents.
BioHarvest Corporate Contact:
Dave Ryan, VP Investor Relations
(604) 622-1186
info@bioharvest.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/286091
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.